uniQure’s (QURE) Buy Rating Reiterated at Guggenheim

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reiterated by equities researchers at Guggenheim in a report issued on Wednesday,Benzinga reports.

Several other equities research analysts have also weighed in on the stock. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $20.00 to $52.00 in a research note on Tuesday. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of uniQure in a report on Tuesday. The Goldman Sachs Group cut their price objective on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald upped their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.33.

uniQure Stock Up 1.5 %

NASDAQ:QURE traded up $0.23 during trading hours on Wednesday, hitting $15.53. The stock had a trading volume of 3,071,166 shares, compared to its average volume of 1,624,749. uniQure has a 1-year low of $3.73 and a 1-year high of $17.39. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market cap of $756.93 million, a PE ratio of -3.06 and a beta of 0.89. The business has a 50 day simple moving average of $6.42 and a two-hundred day simple moving average of $6.15.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Analysts predict that uniQure will post -3.74 EPS for the current year.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds have recently made changes to their positions in the stock. abrdn plc raised its holdings in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after buying an additional 1,528,581 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of uniQure in the 3rd quarter worth approximately $7,360,000. Point72 Asset Management L.P. increased its stake in shares of uniQure by 336.1% in the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares in the last quarter. FMR LLC increased its position in uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 346,274 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in shares of uniQure during the second quarter valued at approximately $815,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.